Nanobiotix

NBTX

시가총액 US$10.8억

PARIS and CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the appointment of Arnd Christ as chief financial officer and member of the Company's executive board, effective October 1, 2026. Mr. Christ brings more than two decades of financial leadership in publicly listed biotechnology companies in Europe and the United States. He succeeds Bart Van Rhijn, who will step down as chief financial & business officer and member of the executive board after five years of service to the Company.

PARIS and CAMBRIDGE, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today provided an update on operational progress and reported financial results for the first six months of 2026.

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)

All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injection procedure, and intratumoral injection was deemed feasible One-year locoregional control rate was 79%, one-year local progression-free survival (LPFS) was 61%, and one-year overall survival (OS) was 70% in evaluable subjects— achieved at a lower re-irradiation dose than patients' prior course of radiotherapy Investigators concluded that JNJ-1900 (NBTXR3 may permit clinically meaningful local control using a substantially lower re-irradiation dose than patients' prior course of radiotherapy Enrollment in the dose-escalation and expansion parts of the study is complete per protocol; following the encourage findings, additional patient enrollment in this study is planned Data presented at the IASLC 2026 World Conference on Lung Cancer PARIS and CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced updated safety and efficacy data from the completed dose-escalation and expansion phases of a Phase 1 study sponsored by The University of Texas MD Anderson Cancer Center (“UT MD Anderson”) evaluating radiotherapy-activated JNJ-1900 (NBTXR3) for patients with inoperable, locoregionally recurrent non-small cell lung cancer (“NSCLC”) amenable to re-irradiation (“reRT”).

PARIS and CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that Company management will participate in a fireside chat at the following investment conference:

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)

PARIS, July 30, 2026 (GLOBE NEWSWIRE) -- In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)

Nanobiotix is rated a strong speculative Buy, driven by risk-adjusted upside from its JNJ-1900 radioenhancer platform in partnership with Janssen. NBTX's lead indication, head and neck cancer, offers a modeled $624M valuation, but lung cancer programs—despite higher risk—represent two-thirds of the $4.5B risk-adjusted opportunity. JNJ-1900's platform potential is vast, with even low-probability broad adoption scenarios materially boosting valuation; upcoming clinical milestones in 2026–2027 are pivotal.

Nanobiotix is evolving into a capital-light, milestone- and royalty-driven oncology platform with JNJ-1900 at its core. JNJ-1900, now led by Johnson & Johnson, targets radioenhancement across multiple solid tumors, with a $2.6B potential milestone structure and double-digit royalties. Recent financing and a May 2026 equity raise extend NBTX's cash runway through 2029, shifting clinical and operational risk to J&J.

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)